SCHEMBL7736066

SCHEMBL7736066

Cc1ccc(C(=O)CCCCCCCBr)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.62
KMT2A Q03164 4/20 0.58
L3MBTL1 Q9Y468 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 1/20 0.53
HSD17B3 P37058 6/20 0.53
HDAC1 Q13547 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
THRA P10827 1/20 0.50
THRB P10828 1/20 0.50
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MEN1 O00255 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7383618 1.00 GSK3B (0.62) GSK3BKMT2AL3MBTL1TDP1LMNA
SCHEMBL11277802 0.94 GSK3B (0.64) GSK3BKMT2ALMNAHSD17B3THRA
SCHEMBL8402203 0.92 KMT2A (0.67) GSK3BKMT2AL3MBTL1TDP1LMNA
SCHEMBL9419411 0.90 KMT2A (0.69) GSK3BKMT2AL3MBTL1TDP1LMNA
SCHEMBL15199328 0.86 GSK3B (0.69) GSK3BKMT2ALMNAMAPTTHRA
SCHEMBL8510520 0.85 HSD17B3 (0.73) GSK3BKMT2AL3MBTL1TDP1LMNA
SCHEMBL9352247 0.85 KMT2A (0.75) GSK3BKMT2AL3MBTL1TDP1LMNA
SCHEMBL9356308 0.85 KMT2A (0.75) GSK3BKMT2AL3MBTL1TDP1LMNA
SCHEMBL2082766 0.85 HSD17B3 (0.73) GSK3BKMT2AL3MBTL1TDP1LMNA
SCHEMBL9352262 0.85 KMT2A (0.75) GSK3BKMT2AL3MBTL1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 US disclosed